| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | IM-101: anti-C5 monoclonal antibody for myasthenia gravis | ||||||
| Antibody | Myasthenia Gravis | Human Complement 5(C5) | Phase 1 | ImmunAbs, Inc. | RS-2025-25454824 | ||
| 2 | Development of therapeutic antibody for the treatment of myasthenia gravis | ||||||
| Antibody | Myasthenia gravis | Disclosure after confidentiality agreement | Candidate | Medytox Inc. | RS-2023-00283006 | ||